Davy James, Managing Editor

Top stories of the week on Specialty Pharmacy Times from May 25 to May 29.

Uncertainty persists in how collagen influences cancer cell behavior.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Treatment advances have caused significant progress in survivorship.

Treatment utilizes immune cells grown from patient bone marrow to treat multiple myeloma.

Protein that helps cancer cells avoid death offers promising target.

Novel drug target found in cells directly responsible for cartilage damage in affected joints.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses potential methods for keeping high cost drugs accessible.

Genetic variant found to be associated with the likelihood of patient response to interferon-beta.

Smokers face high risk of disease recurrence after completing treatment.

Discovery may accelerate search for effective vaccine.

Investigational drug will move to phase 3 studies.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the partnership between the National Association for Specialty Pharmacy and Specialty Pharmacy Times.

Treatment prior to surgery leads to fewer side effects and better quality of life.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Persistent HIV reservoirs present ongoing treatment challenge.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

Drug mitigates elevated cardiovascular risk in infected patients.

Genetic variant regulates response to leading multiple sclerosis therapy.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Paul Sipes, vice president of Spud Software, discusses how specialty pharmacies can best utilize technology to their advantage.

Combination is now being considered for patients who received a liver transplant.

Anti-PDL1 agent with standard chemotherapy combination will now move to multiple phase 3 studies.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

The FDA today amended its breakthrough therapy designation for an experimental hepatitis C drug combination.

Study finds benefits from reduced absenteeism and improved workplace productivity.

Height can impact wait times for transplantation and overall mortality.

Bacterial enzyme could offer new target for treatment of condition.

Economic downturn associated with cancer mortality.

Blood test predicts which patients will respond to interferon.